Isogen plant to answer small-scale sterile filling need
Isogen will start operations in January at a new contract facility in Delaware that will provide small-scale sterile filling services to the pharmaceutical industry.
Archives for November 25, 2008
Aptuit’s API to IND 26 week service
Aptuit presented a seminar at this year’s AAPS explaining how it had implemented its INDiGO programme, which takes an API to IND in 26 weeks, and how it can benefit clients.
Demonstrating “healthcare value” is key to avoiding another Exubera
Pfizer’s Exubera failure need not be the final nail in the coffin for inhaled biopharmaceuticals as long as developers focus on proving “healthcare value” and addressing payer needs, according to Bruckner Group’s David Balekdjian.
AAPS drug delivery award for novel device
MicroCHIPS scooped the drug delivery technology award at this year’s AAPS, after which CEO John Santini spoke to in-PharmaTechnologist.com about the device and what the future holds for the company.
More women now in clinical trials; study
The proportion of women in clinical trials has become more representative, although there are still areas for improvement, according to research by the FDA.
Pharma manufacturing: People on the move
in-PharmaTechnologist.com presents its latest round up of personnel moves in pharmaceutical manufacturing.
Tigermed, OCT and LSK to set up global trials network
Chinese CRO Tigermed Consulting has teamed up with Russian and South Korean counterparts OCT and LSK to establish a global clinical trials network and expand its geographic footprint.
Merrion signs “transformational” deal with Novo for oral insulin
Irish oral dosage specialist Merrion Pharmaceuticals is to develop and commercialise Novo Nordisk’s range of insulin analogues as the Danish firm seeks to tighten its grip on the $9bn (€7bn) a year diabetes market.
MicroCHIPS' CEO responds to AAPS award
After collecting the drug delivery award at this year's AAPS, John Santini, CEO of MicroCHIPS, was on hand to explain what the gong meant to the company.